Lantheus Holdings, Inc. $LNTH Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 88.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,067 shares of the medical equipment provider’s stock after buying an additional 28,138 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Lantheus were worth $3,081,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LNTH. Assenagon Asset Management S.A. purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $65,654,000. Polaris Capital Management LLC acquired a new position in Lantheus during the third quarter worth $32,687,000. Norges Bank purchased a new position in shares of Lantheus during the second quarter worth $32,631,000. Boston Partners grew its stake in shares of Lantheus by 30.5% in the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after buying an additional 134,781 shares in the last quarter. Finally, Frontier Capital Management Co. LLC raised its holdings in shares of Lantheus by 52.1% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 315,513 shares of the medical equipment provider’s stock valued at $25,828,000 after buying an additional 108,060 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Trading Up 1.0%

Shares of NASDAQ:LNTH opened at $69.38 on Monday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company’s 50 day moving average is $66.30 and its two-hundred day moving average is $59.38. The company has a market cap of $4.60 billion, a PE ratio of 29.15 and a beta of -0.08. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Analyst Ratings Changes

LNTH has been the subject of a number of research analyst reports. Truist Financial raised their target price on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Mizuho raised their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $78.00.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.